Navigation Links
Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Date:9/24/2007

ected patients.

About Multiple Myeloma

Multiple Myeloma is a blood malignancy characterized by the accumulation of malignant cells in the bone marrow. The clinical manifestations of the disease are overproduction of immunoglobulin, bone destruction, bone pain, anemia, high calcium levels and kidney dysfunction. The incidence of Multiple Myeloma is especially high in African-Americans, in whom it is the most common blood cancer. Unlike the bone loss associated with other bone tumors, the Myeloma bone lesions are unique in that they do not heal or repair, despite the patients' having many years of complete remission. This may be related to the inhibition and/or loss of the bone-forming cells during disease progression and increased numbers/activity of cells causing bone loss. Thus Myeloma is a disorder that would benefit from therapies that both stimulate bone formation and retard its loss. To date, no such therapies exist and Velcura believes that VEL-0230 may help those suffering from Multiple Myeloma.

For more information on this disease, contact the Multiple Myeloma Research Foundation (http://www.multiplemyeloma.org)

About Velcura Therapeutics, Inc.

Velcura Therapeutics Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti-bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com. Availabl
'/>"/>

SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...23/PRNewswire-FirstCall/--CeptionTherapeutics,Inc....n,Inc.(Nasdaq: CEPH )todayannouncedresultsfromaPha...atreatmentforpediatriceosinophilicesophagitis(EoE)...rimaryendpointsofchangesinesophagealeosinophilleve...atpatientstreatedwithCINQUILshowedastatisticallysi...
(Date:11/23/2009)...re/--AdvancedSterilizationProducts(ASP),aleadinggl...odaytheacquisitionbyitsFrenchaffiliate,ApsisS.A.S....vedisinfectionprocessesandtechnologiestopreventhea...renotdisclosed. ,, GlosterEuropedesignsandmarke...videsdisinfectionofpatientenvironmentssuchashospit...
(Date:11/20/2009)...wire/ -- The United States Court of Appeals for t...ruling yesterday, approving a settlement in the lo...tical litigation against AstraZeneca Pharmaceutica...i-bin/prnh/20080317/AQM144LOGO ) ,, The ruling ...rchased the pharmaceutical giant,s prostate cancer...
Breaking Medicine Technology:Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 3Cooper University Hospital Reduces Costs and Enhances Patient Care with IP Telephony and Wireless Site Survey 54055 1Cooper University Hospital Reduces Costs and Enhances Patient Care with IP Telephony and Wireless Site Survey 54055 2Cooper University Hospital Reduces Costs and Enhances Patient Care with IP Telephony and Wireless Site Survey 54055 3First Ever Downloadable Safety in the Home Guides Available Now From VisionAWARE org 54051 1First Ever Downloadable Safety in the Home Guides Available Now From VisionAWARE org 54051 2McKesson Expands Pharmacy Automation Product Portfolio to Include I V Therapy 13473 1McKesson Expands Pharmacy Automation Product Portfolio to Include I V Therapy 13473 2McKesson Expands Pharmacy Automation Product Portfolio to Include I V Therapy 13473 3
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a bi...commercialization of anti-adhesion, drug delivery ...day that REPEL-CV(R), the company,s,bioresorbable ...ns,following cardiac surgery, has received Health ...undergo open heart surgery. REPEL-CV will be,marke...
..., July 14 MAP,Pharmaceuticals, Inc. (Nasdaq: MAP...linical program to evaluate MAP0004 as a potential...ed and self-administered at home using MAP,Pharmac...pany,s prior Phase,2 efficacy study, MAP0004 provi...ef sustained through at least 24 hours. The study ...
Other Medicine Technology:SyntheMed Receives Canadian Approval for REPEL-CV(R) 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4
(Date:11/23/2009)...-FirstCall/-- ,, DearIsisSupportersandSharehold...ntinuingsupportofIsis.Webelieveweareatoneofthemost...thebeginningofcreatingauniquecompanywithanoveldrug...issueshauntingthepharmaceuticalindustry. ,, Our...shipdrug,mipomersen.Mipomersencontinuestoperformwe...
(Date:11/23/2009)...ylCompanies,thenation,sleadingproviderofoutsourced...edrecognitionasoneofthetopoutsourcingfirmsinhealth...magazine.Berylwasrankedamongthepublication,stop20o...hichenabledittoclimbfromtwelfthplacein2007totenthp...veproducts,suchasitsnewestlaunchofpost-dischargese...
(Date:11/23/2009)...rstCall/--ArcadiaResources,Inc.(NYSEAmex: KAD ),al...esundertheArcadiaHealthCare(SM)()brand,announcedto...haresofitscommonstockandwarrantstopurchasecommonst...nalinvestors,representinggrossproceedstoArcadiaofa...arateSubscriptionAgreementswiththeinvestors,Arcadi...
(Date:11/23/2009)...ascular Services, a division of Baptist Medical Ce...ddition of Aquapheresis Therapy using the Aquadex ...t of patients with fluid overload – helping ... Jackson, Miss. (Vocus) November 2...om fluid overload, time is of the essence. Excess ...
(Date:11/23/2009)...al,sDirectNutritionals,LLC,worldwidedistributorofD...siteCookieDiet.com( www.CookieDiet.com ),todayanno...pularhunger-satisfyingcookiesareavailableonSamsclu...,Sam,sClub. ,, "We,reproudtowelcomeSamsclub.com...l,sCookieDietproducts,andtheonlymembershipdiscount...
Breaking Medicine News(10 mins):Health News:The Beryl Companies Named One of the 'Top 10 Outsourcing Firms' in Healthcare 2Health News:Arcadia Resources Announces Closing of $11.1 Million Financing 2Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 2Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 3Health News:Dr. Siegal's COOKIE DIET(R) Cookies Available at Samsclub.com 2
...rom Australia have made the biggest breakthrough i...of common genes linked to the disease//. Res... Research, working with an international team, con...eveloping breast cancer Dr. Georgia Chenevix-Tr...
... by Cancer Research UK says that obese people are ...nd think they must slim down// only to look good. ...nd that 40% thought looking good was the main reas...ve when it comes to looking after our bodies and t...
...The United States Department of Agriculture (USDA)...al Supplemental Nutrition Program// for Women, Inf...DA's proposal will look at reducing the quantity o...a half dozen eggs to one dozen for children, pregn...
...o Haemorrhagic Fever (CCHF) has killed at least 20...ver reported since it was identified// in 1944, sa...ases of the Ebola-like disease are bound to be re...e, Amasya, Yozagat and Corum have been affected by...
...ing system combining digital photography with Inte...hod to screen for a common childhood oral disease/...toddlers. Early childhood dental caries (E... that results in extensive tooth decay. The condi...
...thers may someday get a personalized menu of foods...ic makeup as a result of new research at Washingto... Researchers used transparent fish embryos to d...the fetus' organs is essentially complete," said B...
Other Medicine News:Health News:Proposal to revamp WIC food package 2Health News:Crimean-Congo Hemorrhagic Fever hits Turkey 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 3Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: